117 related articles for article (PubMed ID: 29795072)
1. Palivizumab prophylaxis, respiratory syncytial virus and subsequent development of asthma.
Igde M; Kabasakal H; Ozturk O; Karatekin G; Aygun C
Minerva Pediatr; 2018 Jun; 70(3):252-259. PubMed ID: 29795072
[TBL] [Abstract][Full Text] [Related]
2. Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study.
Mochizuki H; Kusuda S; Okada K; Yoshihara S; Furuya H; Simões EAF;
Am J Respir Crit Care Med; 2017 Jul; 196(1):29-38. PubMed ID: 28152315
[TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial.
Scheltema NM; Nibbelke EE; Pouw J; Blanken MO; Rovers MM; Naaktgeboren CA; Mazur NI; Wildenbeest JG; van der Ent CK; Bont LJ
Lancet Respir Med; 2018 Apr; 6(4):257-264. PubMed ID: 29500030
[TBL] [Abstract][Full Text] [Related]
4. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
[TBL] [Abstract][Full Text] [Related]
5. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants.
Yoshihara S; Kusuda S; Mochizuki H; Okada K; Nishima S; Simões EA;
Pediatrics; 2013 Nov; 132(5):811-8. PubMed ID: 24127479
[TBL] [Abstract][Full Text] [Related]
6. Palivizumab prophylaxis in preterm infants and subsequent wheezing/asthma: 10-year follow-up study.
Kato M; Mochizuki H; Kama Y; Kusuda S; Okada K; Yoshihara S; Furuya H; Simões EAF;
Pediatr Pulmonol; 2024 Mar; 59(3):743-749. PubMed ID: 38116923
[TBL] [Abstract][Full Text] [Related]
7. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children.
Simões EA; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick L; Groothuis JR;
J Allergy Clin Immunol; 2010 Aug; 126(2):256-62. PubMed ID: 20624638
[TBL] [Abstract][Full Text] [Related]
8. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
Blanken MO; Rovers MM; Molenaar JM; Winkler-Seinstra PL; Meijer A; Kimpen JL; Bont L;
N Engl J Med; 2013 May; 368(19):1791-9. PubMed ID: 23656644
[TBL] [Abstract][Full Text] [Related]
9. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
[TBL] [Abstract][Full Text] [Related]
11. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
Resch B
Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
[TBL] [Abstract][Full Text] [Related]
12. RSV immunoprophylaxis: does the benefit justify the cost?
Meissner HC; Kimberlin DW
Pediatrics; 2013 Nov; 132(5):915-8. PubMed ID: 24127478
[No Abstract] [Full Text] [Related]
13. Long term follow-up of Palivizumab administration in children born at 29-32 weeks of gestation.
Bar-Yoseph R; Haddad J; Hanna M; Kessel I; Kugelman A; Hakim F; Bentur L
Respir Med; 2019 Apr; 150():149-153. PubMed ID: 30961942
[TBL] [Abstract][Full Text] [Related]
14. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
15. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
[TBL] [Abstract][Full Text] [Related]
17. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks.
Blanken M; Rovers M; Sanders E; Bont L
Contemp Clin Trials; 2012 Nov; 33(6):1287-92. PubMed ID: 22820319
[TBL] [Abstract][Full Text] [Related]
18. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
[TBL] [Abstract][Full Text] [Related]
19. Factors related to compliance with palivizumab prophylaxis for respiratory syncytial virus (RSV) infection - data from Poland.
Borecka R; Lauterbach R; Helwich E
Dev Period Med; 2016; 20(3):181-190. PubMed ID: 27941187
[TBL] [Abstract][Full Text] [Related]
20. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
